Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis

Narong Maneeton,1 Benchalak Maneeton,1 Suwannee Putthisri,2 Sirijit Suttajit,1 Surinporn Likhitsathian,1 Manit Srisurapanont1 1Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2Department of Psychiatry, Faculty of Medicine, Ramathibodi Hospital, Mahidol Un...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maneeton N, Maneeton B, Putthisri S, Suttajit S, Likhitsathian S, Srisurapanont M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Aberrant Behavior Checklist ABC Children’s Yale–Brown Obsessive Compulsive Scale CY-BOCS efficacy acceptability tolerability. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/be2d8b7b846d4c668250f3bf181e7c41
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:be2d8b7b846d4c668250f3bf181e7c41
record_format	dspace
spelling	oai:doaj.org-article:be2d8b7b846d4c668250f3bf181e7c412021-12-02T01:58:33ZAripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis1178-2021https://doaj.org/article/be2d8b7b846d4c668250f3bf181e7c412018-11-01T00:00:00Zhttps://www.dovepress.com/aripiprazole-in-acute-treatment-of-children-and-adolescents-with-autis-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Narong Maneeton,1 Benchalak Maneeton,1 Suwannee Putthisri,2 Sirijit Suttajit,1 Surinporn Likhitsathian,1 Manit Srisurapanont1 1Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2Department of Psychiatry, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Background: Recent randomized controlled trials indicated that aripiprazole was the effective treatment for children and adolescents with autism spectrum disorder (ASD).Objective: This study systematically reviewed the efficacy, acceptability and tolerability of aripiprazole in treatment of ASD children and adolescents.Data sources: Electronic search of databases including, Scopus, PubMed, CINAHL and Cochrane Controlled Trials Register was performed in July 2017.Methods: The full-text versions of included trials were meticulously evaluated and extracted. The main efficacious outcomes consisted of pooled mean change scores of the standardized rating scales for ASD and the pooled response rate.Results: A total of 408 randomized patients from eligible trials were included for synthesizing in this meta-analysis. The pooled mean change scores in aripiprazole-treated group for the Aberrant Behavior Checklist (ABC)-Irritability, ABC-Hyperactivity/noncompliance, ABC-Inappropriate speech and ABC-Stereotypic behavior were significantly greater than those of the placebo-treated group. Unfortunately, the significant difference between two groups was not found for ABC-Lethargy/social withdrawal. The overall pooled response rate of the aripiprazole-treated group was significantly higher than that of the placebo-treated group. The pooled overall discontinuation rate in aripiprazole-treated group was significantly better than that of placebo-treated group. The pooled discontinuation rates due to adverse events in aripiprazole-treated group significantly differed from the placebo-treated group (RR [95% CI] of 1.43 [0.65, 3.18], I2=0%).Limitation: A small number of studies were gathered in this review.Conclusion: Aripiprazole has efficacy in the treatment of behavioral disturbances, including irritability, hyperactivity/noncompliance, inappropriate speech and stereotypic behavior found in ASD children and adolescents; however, it could not improve the lethargy/social withdrawal in such patients. The present evidence also indicates that it is safe, acceptable and tolerable in such treatment. As a small sample size, further well-defined and large sample size studies should be conducted to warrant those findings. Keywords: Aberrant Behavior Checklist, ABC, Children’s Yale–Brown Obsessive Compulsive Scale, CY-BOCS, efficacy, acceptability, tolerabilityManeeton NManeeton BPutthisri SSuttajit SLikhitsathian SSrisurapanont MDove Medical PressarticleAberrant Behavior ChecklistABCChildren’s Yale–Brown Obsessive Compulsive ScaleCY-BOCSefficacyacceptabilitytolerability.Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 3063-3072 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Aberrant Behavior Checklist ABC Children’s Yale–Brown Obsessive Compulsive Scale CY-BOCS efficacy acceptability tolerability. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Aberrant Behavior Checklist ABC Children’s Yale–Brown Obsessive Compulsive Scale CY-BOCS efficacy acceptability tolerability. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Maneeton N Maneeton B Putthisri S Suttajit S Likhitsathian S Srisurapanont M Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis
description	Narong Maneeton,1 Benchalak Maneeton,1 Suwannee Putthisri,2 Sirijit Suttajit,1 Surinporn Likhitsathian,1 Manit Srisurapanont1 1Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2Department of Psychiatry, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Background: Recent randomized controlled trials indicated that aripiprazole was the effective treatment for children and adolescents with autism spectrum disorder (ASD).Objective: This study systematically reviewed the efficacy, acceptability and tolerability of aripiprazole in treatment of ASD children and adolescents.Data sources: Electronic search of databases including, Scopus, PubMed, CINAHL and Cochrane Controlled Trials Register was performed in July 2017.Methods: The full-text versions of included trials were meticulously evaluated and extracted. The main efficacious outcomes consisted of pooled mean change scores of the standardized rating scales for ASD and the pooled response rate.Results: A total of 408 randomized patients from eligible trials were included for synthesizing in this meta-analysis. The pooled mean change scores in aripiprazole-treated group for the Aberrant Behavior Checklist (ABC)-Irritability, ABC-Hyperactivity/noncompliance, ABC-Inappropriate speech and ABC-Stereotypic behavior were significantly greater than those of the placebo-treated group. Unfortunately, the significant difference between two groups was not found for ABC-Lethargy/social withdrawal. The overall pooled response rate of the aripiprazole-treated group was significantly higher than that of the placebo-treated group. The pooled overall discontinuation rate in aripiprazole-treated group was significantly better than that of placebo-treated group. The pooled discontinuation rates due to adverse events in aripiprazole-treated group significantly differed from the placebo-treated group (RR [95% CI] of 1.43 [0.65, 3.18], I2=0%).Limitation: A small number of studies were gathered in this review.Conclusion: Aripiprazole has efficacy in the treatment of behavioral disturbances, including irritability, hyperactivity/noncompliance, inappropriate speech and stereotypic behavior found in ASD children and adolescents; however, it could not improve the lethargy/social withdrawal in such patients. The present evidence also indicates that it is safe, acceptable and tolerable in such treatment. As a small sample size, further well-defined and large sample size studies should be conducted to warrant those findings. Keywords: Aberrant Behavior Checklist, ABC, Children’s Yale–Brown Obsessive Compulsive Scale, CY-BOCS, efficacy, acceptability, tolerability
format	article
author	Maneeton N Maneeton B Putthisri S Suttajit S Likhitsathian S Srisurapanont M
author_facet	Maneeton N Maneeton B Putthisri S Suttajit S Likhitsathian S Srisurapanont M
author_sort	Maneeton N
title	Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis
title_short	Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis
title_full	Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis
title_fullStr	Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis
title_full_unstemmed	Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis
title_sort	aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/be2d8b7b846d4c668250f3bf181e7c41
work_keys_str_mv	AT maneetonn aripiprazoleinacutetreatmentofchildrenandadolescentswithautismspectrumdisorderasystematicreviewandmetaanalysis AT maneetonb aripiprazoleinacutetreatmentofchildrenandadolescentswithautismspectrumdisorderasystematicreviewandmetaanalysis AT putthisris aripiprazoleinacutetreatmentofchildrenandadolescentswithautismspectrumdisorderasystematicreviewandmetaanalysis AT suttajits aripiprazoleinacutetreatmentofchildrenandadolescentswithautismspectrumdisorderasystematicreviewandmetaanalysis AT likhitsathians aripiprazoleinacutetreatmentofchildrenandadolescentswithautismspectrumdisorderasystematicreviewandmetaanalysis AT srisurapanontm aripiprazoleinacutetreatmentofchildrenandadolescentswithautismspectrumdisorderasystematicreviewandmetaanalysis
_version_	1718402800275161088

Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis

Ejemplares similares